Intervention | Intention to treat | Per protocola | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
n/N | % | OR | 95%CI | P-value | n/N | % | OR | 95%CI | P-value | |
Survey 28Â months | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Standard LLINb | 1643/2032 | 80.9 | 1 |  |  | 762/962 | 79.2 | 1 |  |  |
 PBO-Pyrethroid LLINc | 1280/1848 | 69.3 | 0.45 | 0.21–0.95 | 0.0364 | 507/755 | 67.2 | 0.43 | 0.22–0.84 | 0.0151 |
 No IRSd | 1441/1897 | 76.0 | 1 |  |  | 663/881 | 75.3 | 1 |  |  |
 IRSe | 1482/1983 | 74.7 | 0.79 | 0.44–1.41 | 0.4172 | 606/836 | 72.5 | 0.71 | 0.39–1.30 | 0.2615 |
 Interaction coefficient |  |  | 1.38 | 0.53–3.69 | 0.505 |  |  | 1.59 | 0.62–4.07 | 0.3239 |
Survey 33Â months | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Standard LLINb | 1045/1784 | 58.6 | 1 |  |  | 291/509 | 57.2 | 1 |  |  |
 PBO-Pyrethroid LLINc | 901/1807 | 49.9 | 0.60 | 0.32–1.13 | 0.1131 | 200/453 | 44.2 | 0.34 | 0.16–0.71 | 0.0051 |
 No IRSd | 1009/1776 | 56.8 | 1 |  |  | 257/500 | 51.4 | 1 |  |  |
 IRSe | 937/1815 | 51.6 | 0.52 | 0.25–1.07 | 0.0747 | 234/462 | 50.7 | 0.57 | 0.31–1.06 | 0.0736 |
 Interaction coefficient |  |  | 1.78 | 0.71–4.49 | 0.2131 |  |  | 3.11 | 1.18–8.20 | 0.0230 |